Oramed Pharmaceuticals Inc Stock Price, News & Analysis

Oramed Pharmaceuticals (Nasdaq: ORMP) announced a significant achievement on May 24, 2022, as the US Patent and Trademark Office granted them a patent for methods and compositions aimed at treating diabetes mellitus. This patent covers oral pharmaceutical solutions that combine insulin with Glucagon-like Peptide 1 (GLP-1). Oramed is pioneering oral delivery systems to transform diabetes treatment, particularly with its lead candidate, ORMD-0801, currently in pivotal Phase 3 trials, along with the development of an oral GLP-1 analog capsule, ORMD-0901.

Oramed Pharmaceuticals (Nasdaq:ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami, Florida. The presentation is set for 12:00 p.m. E.T. and will be available for streaming for 90 days. Known for its oral drug delivery innovations, Oramed aims to transform diabetes treatment with its lead candidate, ORMD-0801, currently in Phase 3 trials.

Oramed Pharmaceuticals has completed enrollment for its Phase 3 ORA-D-013-1 study of the oral insulin capsule, ORMD-0801, with 710 patients, exceeding the initial goal of 675. This study focuses on type 2 diabetes patients with inadequate glycemic control, aiming for efficacy results in January 2023. The oral insulin could significantly improve patient experience and outcomes compared to injectable insulin, potentially becoming the first FDA-approved oral insulin.

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) has received a patent from the European Patent Office for its innovative methods to treat non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis. This patent complements a previously granted U.S. patent and is pending approval in various key markets. Additionally, Oramed has successfully completed 100% enrollment in its Phase 2 trial for oral insulin ORMD-0801, targeting type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The NASH drug market is projected to reach $84 billion by 2029.

Oramed Pharmaceuticals (Nasdaq: ORMP) will host a webinar on March 30, 2022, at 12:00 p.m. ET, featuring experts discussing the need for oral insulin in type 2 diabetes. Presenters include Dr. Anne Peters from USC and Dr. Alexander Fleming, formerly with the FDA. They will address the treatment landscape and the potential of Oramed's oral insulin candidate, ORMD-0801, currently in Phase 3 trials. A live Q&A session will follow. For registration, visit here.

Oramed Pharmaceuticals (Nasdaq: ORMP) has successfully completed patient enrollment for its Phase 2 trial of the oral insulin capsule ORMD-0801, targeting non-alcoholic steatohepatitis (NASH) in Type 2 diabetes patients. NASH affects 4 to 17 million adults in the U.S., with no approved treatments currently available. The trial, conducted in the U.S. and Israel, will evaluate ORMD-0801's safety and efficacy after 12 weeks of dosing. The global NASH drug market is projected to reach $84 billion by 2029. Oramed anticipates reporting topline results that support previous efficacy findings.

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) announced that CEO Nadav Kidron will present at the Barclays Global Healthcare Conference in Miami, Florida, from March 15-17, 2022. Kidron's presentation is scheduled for Tuesday, March 15, 2022, at 3:50 p.m. Eastern time. The event will be webcasted and available for view for 90 days. Oramed is a pioneer in oral drug delivery systems, particularly targeting diabetes treatment with its lead oral insulin candidate, ORMD-0801, currently in pivotal Phase 3 studies.

Oramed Pharmaceuticals (NASDAQ: ORMP) provided a shareholder update highlighting significant advancements in 2021. The company is advancing its oral insulin and COVID-19 vaccine candidates through pivotal trials, expecting topline results in H2 2022. ORMP has achieved over 75% enrollment in its Phase 3 oral insulin trial and is progressing with its oral COVID-19 vaccine in South Africa. With approximately $174 million in cash as of December 2021, Oramed is well-positioned for upcoming milestones, including key clinical results and potential emergency use authorization for its vaccine.